Trials / Recruiting
RecruitingNCT07037277
C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV
An Evaluation of Bemnifosbuvir-Ruzasvir (BEM/RZR) Versus Sofosbuvir-Velpatasvir (SOF/VEL) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in a Phase 3 Randomized, Controlled, Open-label Study
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 880 (estimated)
- Sponsor
- Atea Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the efficacy and safety of BEM/RZR to SOF/VEL in adults with chronic HCV.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bemnifosbuvir-Ruzasvir | BEM/RZR Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 8 weeks (in those without cirrhosis) or 12 weeks (in those with compensated cirrhosis) |
| DRUG | Sofosbuvir-Velpatasvir | SOF/VEL Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 12 weeks |
Timeline
- Start date
- 2025-06-02
- Primary completion
- 2026-12-01
- Completion
- 2027-03-01
- First posted
- 2025-06-25
- Last updated
- 2026-04-13
Locations
106 sites across 16 countries: France, Germany, Greece, India, Malaysia, Moldova, Pakistan, Poland, Romania, South Africa, South Korea, Spain, Thailand, Turkey (Türkiye), Ukraine, Vietnam
Source: ClinicalTrials.gov record NCT07037277. Inclusion in this directory is not an endorsement.